Latigo Biotherapeutics is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction – addressing significant unmet societal and medical needs. We aim to build one of the broadest pipelines of pain therapeutics which, we believe, combined with our management team’s deep expertise in pain biology, clinical translation, and trial execution, positions us to deliver meaningful patient benefit and to change the current treatment paradigm of pain medicines.